Urologia Internationalis
Original Paper
Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder CancerStangl-Kremser J.a · Mari A.a · D’Andrea D.a · Kimura S.a · Resch I.a · Shariat S.F.a,b,c,d · Klatte T.aaDepartment of Urology, Medical University of Vienna, Vienna, Austria
bKarl Landsteiner Society, Urology and Andrology, Vienna, Austria cDepartment of Urology, Weill Cornell Medical College, New York, NY, USA dDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA |
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: February 02, 2018
Accepted: April 05, 2018
Published online: August 08, 2018
Issue release date: August 2018
Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 0
ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)
For additional information: https://www.karger.com/UIN
Abstract
Purpose: We hypothesized sarcopenia as predictive factor as a response to upfront chemotherapy of muscle-invasive urothelial bladder cancer (MIBC). Methods: We retrospectively studied 30 patients who received upfront cisplatin-based chemotherapy for MIBC (pT2–4 N0/+ M0) before planned radical cystectomy. Skeletal muscle index (SMI) was calculated by CT at study baseline and following completion of chemotherapy. Patients were stratified according to the presence of sarcopenia. Endpoints included clinical and pathological response. Results: Sixteen of the 30 patients (53.3%) had sarcopenia at baseline. The median SMI was 51.2 cm2/m2 (IQR 45.6–57.9). Throughout the course of chemotherapy, 22 patients (73.3%) experienced a decline in SMI, which ranged from 1 to 20% (median decline 3%, p < 0.01). All 16 patients with baseline sarcopenia persisted, while 5 of 14 patients (35.7%) without baseline sarcopenia became sarcopenic (p = 0.06). None of the clinical variables were predictive of clinical or pathological response, including SMI (p = 0.78 and p = 0.59), sarcopenia (p = 0.65 and p = 0.16) and SMI kinetics (p = 0.54 and p = 0.77). Conclusion: Sarcopenia is present in a considerable proportion of patients with MIBC undergoing upfront cisplatin-based chemotherapy before planned RC. SMI decreases during treatment, but neither baseline SMI nor its kinetics is associated with response to chemotherapy.
© 2018 S. Karger AG, Basel
Related Articles:
References
-
Gomez-Perez SL, Haus JM, Sheean P, Patel B, Mar W, Chaudhry V, et al: Measuring abdominal circumference and skeletal muscle from a single cross-sectional computed tomography image: a step-by-step guide for clinicians using National Institutes of Health ImageJ. JPEN J Parenter Enteral Nutr 2016; 40: 308–318.
-
Taguchi S, Akamatsu N, Nakagawa T, Gonoi W, Kanatani A, Miyazaki H, et al: Sarcopenia evaluated using the skeletal muscle index is a significant prognostic factor for metastatic urothelial carcinoma. Clin Genitourin Cancer 2016; 14: 237–243.
-
International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder, et al: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29: 2171–2177.
-
Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al: Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 2004; 97: 2333–2338.
-
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al: Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489–495.
-
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.
-
Bensalah K, Montorsi F, Shariat SF: Challenges of cancer biomarker profiling. Eur Urol 2007; 52: 1601–1609.
-
Sikic D, Wach S, Taubert H, Richterstetter M, Kunath F, Lieb V, et al: How octogenarians with bladder cancer are treated in a maximum-care hospital: the real-life experience. Urol Int 2017; 98: 262–267.
-
Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, et al: Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010; 183: 68–75.
-
Karakiewicz PI, Shariat SF, Palapattu GS, Perrotte P, Lotan Y, Rogers CG, et al: Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol 2006; 50: 1254–1260;discussion 1261–1262.
-
Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y: Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007; 20: 445–459.
-
Smith AB, Deal AM, Yu H, Boyd B, Matthews J, Wallen EM, et al: Sarcopenia as a predictor of complications and survival following radical cystectomy. J Urol 2014; 191: 1714–1720.
-
Psutka SP, Carrasco A, Schmit GD, Moynagh MR, Boorjian SA, Frank I, et al: Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer 2014; 120: 2910–2918.
-
Zargar H, Almassi N, Kovac E, Ercole C, Remer E, Rini B, et al: Change in psoas muscle volume as a predictor of outcomes in patients treated with chemotherapy and radical cystectomy for muscle-invasive bladder cancer. Bladder Cancer 2017; 3: 57–63.
-
Fukushima H, Koga F: Impact of sarcopenia in the management of urological cancer patients. Expert Rev Anticancer Ther 2017; 17: 455–466.
Article / Publication Details
Received: February 02, 2018
Accepted: April 05, 2018
Published online: August 08, 2018
Issue release date: August 2018
Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 0
ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)
For additional information: https://www.karger.com/UIN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
